Literature DB >> 10856441

16(R)-hydroxy-5,8,11,14-eicosatetraenoic acid, a new arachidonate metabolite in human polymorphonuclear leukocytes.

M M Bednar1, C E Gross, M K Balazy, Y Belosludtsev, D T Colella, J R Falck, M Balazy.   

Abstract

Intact human polymorphonuclear leukocytes (PMNL) incubated with substimulatory amounts of arachidonic acid in the absence of a calcium ionophore formed four metabolites that were isolated by reverse-phase HPLC and characterized structurally by GC/MS. A major metabolite eluting as the most abundant peak of radioactivity lacked UV chromophores above 215 nm, and its formation was sensitive to 2-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF525A) but not 3-amino-1-[m(trifluoromethyl)phenyl]-2-pyrazoline (BW755C), suggesting that it was likely to be a product of cytochrome P450. The GC/MS analysis revealed the presence of two components: 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) and 16-hydroxy-5,8,11,14-eicosatetraenoic acid (16-HETE) in an approximate ratio of 4:1. The minor metabolites were identified as 15-HETE and 5-HETE. Although 20-HETE has been observed previously as a product of arachidonic acid metabolism in PMNL, the occurrence of 16-HETE was a novel finding. The stereochemistry of the hydroxyl group in PMNL-derived 16-HETE was established by analysis of 1-pentafluorobenzyl-16-naphthoyl derivatives on a chiral-phase chromatographic column and comparison with authentic synthetic stereoisomers. The PMNL-derived radioactive metabolite co-eluted with the synthetic 16(R)-HETE stereoisomer. Analysis of the total lipid extracts from intact PMNL followed by mild alkaline hydrolysis resulted in detectable amounts of 16-HETE (108+/-26 pg/10(8) cells) and 20-HETE (341+/-69 pg/10(8) cells), which suggested that these HETEs were formed from endogenous arachidonic acid and esterified within PMNL lipids. Thus, in contrast to calcium ionophore-stimulated neutrophils that generate large amounts of 5-lipoxygenase products, the intact PMNL generate 20-HETE and 16(R)-HETE via a cytochrome P450 omega- and omega-4 oxygenase(s).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856441     DOI: 10.1016/s0006-2952(00)00345-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Lipid mediators in immune regulation and resolution.

Authors:  Derek W Gilroy; David Bishop-Bailey
Journal:  Br J Pharmacol       Date:  2019-03-01       Impact factor: 8.739

Review 2.  Role of oxylipins in cardiovascular diseases.

Authors:  Mohammed A Nayeem
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

Review 3.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

4.  Study on the levels of N-nitrosamine compounds and untargeted metabolomics in patients with colorectal cancer.

Authors:  Zhi Luo; Hetao Wang; Simin Lin; Lili Liao; Lishan Cai; Xiaoxu Zhang; Yangying Tan; Mei Shen
Journal:  Anal Bioanal Chem       Date:  2022-02-16       Impact factor: 4.478

Review 5.  Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids.

Authors:  Paul R S Baker; Francisco J Schopfer; Valerie B O'Donnell; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2008-12-10       Impact factor: 7.376

Review 6.  Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles.

Authors:  Sherif M Shoieb; Mahmoud A El-Ghiaty; Ayman O S El-Kadi
Journal:  Emergent Mater       Date:  2020-11-17

7.  Ornithine α-Ketoglutarate Alleviates Inflammation via Regulating Ileal Mucosa Microbiota and Metabolites in Enterotoxigenic Escherichia coli-Infected Pigs.

Authors:  Yuying Li; Xuetai Bao; Fan Yang; Junquan Tian; Wenxuan Su; Jie Yin; Kang Yao; Tiejun Li; Yulong Yin
Journal:  Front Nutr       Date:  2022-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.